It takes a village to raise awareness of and to address surface contamination of hazardous drugs

Abstract

Get full access to this article

View all access options for this article.

References

Hazardous drugs – handling in healthcare settings. United States Pharmacopoeia, www.usp.org/sites/default/files/usp_pdf/EN/m7808_pre-post.pdf (accessed 25 June 2017).

Clark

Sessink

. Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents. J Oncol Pharm Pract 2013; 19: 99–104.

Sessink

Trahan

Coyne

. Reduction in surface contamination with cyclophosphamide in 30 US Hospital pharmacies following implementation of a closed-system drug transfer device. Hosp Pharm 2013; 48: 204–212.

Sessink

Connor

Jorgenson

et al.

Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device. J Oncol Pharm Pract 2011; 17: 39–48.

Zock

Soefje

Rickabaugh

. Evaluation of surface contamination with cyclophosphamide following simulated hazardous drug preparation activities using two closed-system products. J Oncol Pharm Pract 2011; 17: 49–54.

Connor

Anderson

Sessink

et al.

Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am J Health Syst Pharm 2002; 59: 68–72.

Yoshida

Tei

Mochizuki

et al.

Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Ann Occup Hyg 2009; 53: 153–160.

Miyake

Iwamoto

Tanimura

et al.

Impact of closed-system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus 2013; 2: 273–273.

Wick

Slawson

Jorgenson

et al.

Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm 2003; 60: 2314–2320.

10.

Yoshida

Koda

Nishida

et al.

Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. J Oncol Pharm Pract 2011; 17: 29–38.

11.

Favier

Labrosse

Gilles-Afchain

et al.

The PhaSeal(R) system: impact of its use on workplace contamination and duration of chemotherapy preparation. J Oncol Pharm Pract 2012; 18: 37–45.

12.

Salch S, Zamboni WC and Eckel SE. Identifying pharmacy practice patterns and predictors associated with surface contamination of hazardous drugs in pharmacies: a descriptive summary of five commonly used antineoplastic agents. In: ASHP Midyear Meeting, Las Vegas, NV, 4–6 December 2016.